At $300,000 a year, Sarepta’s new drug is considered a steal By: MarketWatch September 20, 2016 at 11:50 AM EDT Eteplirsen could have been more than twice the price, an analyst said. Read More >> Related Stocks: Gilead Sciences Mylan Sarepta Therapeutics